D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

BenzingaDec 6 20:16 · Ratings

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen PharmaDec 6 13:00

UroGen Pharma Announces UGN-102 Long-Term Results In The Phase 3 ENVISION Trial, Potentially Paving The Way For First FDA-Approved Treatment For LG-IR-NMIBC; UGN-102 Demonstrated 82.3% Duration Of Response At 12 Months In Patients Who Achieved...

BenzingaDec 6 04:18

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

UroGen PharmaDec 5 13:00

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

UroGen PharmaDec 2 13:00

UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO

BenzingaNov 26 21:09